Morphic Holding

Morphic Holding EBIT per Share

Delisted

The EBIT per Share of Morphic Holding (MORF) as of Oct 21, 2026 is -4.25 USD. In the previous year, EBIT per Share was -1.67 USD — a change of 155.01% (lower).

EBIT per Share

-4.25USD

YoY

155.01%

Last updated:

EBIT per Share of Morphic Holding is 2023 -4.25 USD. EBIT per Share of Morphic Holding was 2022 -1.67 USD. It decreases by 155.01% lower compared to the previous year.

The Morphic Holding EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2022
-1.67 USD
Jan 1, 2023
-4.25 USD
Jan 1, 2024 (e)
-5.45 USD
Jan 1, 2025 (e)
-5.92 USD
Jan 1, 2026 (e)
-6.48 USD
Jan 1, 2027 (e)
-7.44 USD
Jan 1, 2028 (e)
-5.39 USD
Jan 1, 2029 (e)
-3.07 USD
The Morphic Holding EBIT per Share history
YEAREBIT per ShareYoY
est-3.07USD-43.08%
est-5.39USD-27.50%
est-7.44USD+14.72%
est-6.48USD+9.51%
est-5.92USD+8.68%
est-5.45USD+27.99%
-4.25USD+155.01%
-1.67USD-37.31%
-2.66USD+74.86%
-1.52USD-48.18%
-2.94USD-88.08%
-24.63USD+3,230.05%
-0.74USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Morphic Holding Stock analysis

What does Morphic Holding do? Morphic Holding Inc. is a pharmaceutical company that focuses on developing therapies for serious diseases. The company was founded in 2015 and is based in Waltham, Massachusetts. The company's business model is centered around developing drugs based on "Morphic Molecules" that are specifically designed to interact with certain target proteins in the body. These molecules aim to improve the treatment of diseases such as autoimmune diseases and fibrosis. Morphic Holding Inc. collaborates closely with leading scientists in the field of structural biology to develop new therapy options for patients. The company has formed partnerships with Biogen, Janssen Biotech, and AbbVie to collaboratively develop new medications. In addition to partnering with other leading companies in the healthcare industry, Morphic Holding Inc. also maintains its own research department focused on the discovery and development of new compounds. The company has applied for and been granted several patents for its "Morphic Molecules," further strengthening its ability to develop innovative therapies for serious diseases. One of Morphic Holding Inc.'s current products is a drug for the treatment of cystic fibrosis that is still in the development phase. The company is working to advance its research and development in this area to continue offering innovative therapies for patients. Morphic Holding Inc. is also involved in biotechnological development and offers services to assist other companies in developing new compounds. These services include the identification and validation of target proteins, the design and synthesis of molecules, and the optimization of drug properties. In conclusion, Morphic Holding Inc. is an emerging force in the pharmaceutical development field. The company has a unique approach to drug development and has already established partnerships with other companies and leading research institutions to develop new therapy options for patients. With its commitment to innovation and research, Morphic Holding Inc. is likely to continue making significant advancements in the field of medicine in the future. Morphic Holding is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Morphic Holding stock

EBIT per Share of Morphic Holding is -4.25 USD in 2023.

EBIT per Share of Morphic Holding changed from -1.67 USD to -4.25 USD, representing a 155.01% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Morphic Holding since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Morphic Holding

All Key Metrics — Morphic Holding